Landscape Capital Management L.L.C. Invests $435,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Landscape Capital Management L.L.C. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, Holdings Channel reports. The institutional investor purchased 3,963 shares of the medical equipment provider’s stock, valued at approximately $435,000.

Several other hedge funds also recently modified their holdings of the company. Farallon Capital Management LLC raised its position in Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after purchasing an additional 1,269,900 shares during the last quarter. Swedbank AB acquired a new stake in Lantheus during the 1st quarter worth approximately $26,346,000. Vanguard Group Inc. boosted its position in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after buying an additional 389,828 shares during the period. Point72 Asset Management L.P. bought a new stake in Lantheus during the 2nd quarter worth approximately $26,794,000. Finally, 2Xideas AG acquired a new position in Lantheus in the 1st quarter valued at approximately $10,642,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of a number of recent research reports. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Truist Financial reissued a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Stock Up 3.7 %

Lantheus stock opened at $90.52 on Monday. The company has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The firm’s fifty day moving average is $103.13 and its 200 day moving average is $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.